A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

John M. Bennett, Patrick Byrne, Ajit Desai, Charles White, Ronald DeConti, Charles Vogel, Edward Krementz, Franco Muggia, James Doroshow, David Plotkin, Harvey Golomb, Hyman Muss, Harvey Brodovsky, Richard Gams, Lee Roy Horgan, Shelley Bryant, Arnold Weiss, Kenneth Cartwright, Gary Dukart

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were postmenopausal and 44% of CNF patients and 57% of CAF patients were estrogen receptor (ER) negative. Slightly over 30% of all patients had received hormonal therapy or chemotherapy in an adjuvant setting. Hematologic toxicity was similar in regard to platelet counts but slightly lower nadirs were experienced with CNF therapy than with CAF. However, there were fewer dosage decreases with CNF. Significantly less nausea and vomiting were observed with the CNF regimen compared to CAF. Moreover, alopecia was reduced appreciably in patients who received CNF. The response rate to CNF for the first 38 eligible and evaluable patients was 42%, and for 53 eligible and evaluable patients who received CAF the response rate was 45%, a non-significant difference. Median response durations were similar also, 140 days for CNF and 168 days for the CAF regimen. Time to treatment failure was similar for both regimens. CNF is an effective regimen for patients with advanced breast cancer, with less toxicity than CAF.

Original languageEnglish
Pages (from-to)179-185
Number of pages7
JournalInvestigational New Drugs
Volume3
Issue number2
DOIs
StatePublished - Jun 1 1985

Fingerprint

Mitoxantrone
Fluorouracil
Doxorubicin
Cyclophosphamide
Multicenter Studies
Breast Neoplasms
Alopecia

Keywords

  • Adriamycin
  • advanced breast cancer
  • combination chemotherapy
  • Novantrone

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. / Bennett, John M.; Byrne, Patrick; Desai, Ajit; White, Charles; DeConti, Ronald; Vogel, Charles; Krementz, Edward; Muggia, Franco; Doroshow, James; Plotkin, David; Golomb, Harvey; Muss, Hyman; Brodovsky, Harvey; Gams, Richard; Horgan, Lee Roy; Bryant, Shelley; Weiss, Arnold; Cartwright, Kenneth; Dukart, Gary.

In: Investigational New Drugs, Vol. 3, No. 2, 01.06.1985, p. 179-185.

Research output: Contribution to journalArticle

Bennett, JM, Byrne, P, Desai, A, White, C, DeConti, R, Vogel, C, Krementz, E, Muggia, F, Doroshow, J, Plotkin, D, Golomb, H, Muss, H, Brodovsky, H, Gams, R, Horgan, LR, Bryant, S, Weiss, A, Cartwright, K & Dukart, G 1985, 'A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer', Investigational New Drugs, vol. 3, no. 2, pp. 179-185. https://doi.org/10.1007/BF00174167
Bennett, John M. ; Byrne, Patrick ; Desai, Ajit ; White, Charles ; DeConti, Ronald ; Vogel, Charles ; Krementz, Edward ; Muggia, Franco ; Doroshow, James ; Plotkin, David ; Golomb, Harvey ; Muss, Hyman ; Brodovsky, Harvey ; Gams, Richard ; Horgan, Lee Roy ; Bryant, Shelley ; Weiss, Arnold ; Cartwright, Kenneth ; Dukart, Gary. / A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. In: Investigational New Drugs. 1985 ; Vol. 3, No. 2. pp. 179-185.
@article{752b3044208e4af4b4a83f0be2f0052e,
title = "A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer",
abstract = "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were postmenopausal and 44{\%} of CNF patients and 57{\%} of CAF patients were estrogen receptor (ER) negative. Slightly over 30{\%} of all patients had received hormonal therapy or chemotherapy in an adjuvant setting. Hematologic toxicity was similar in regard to platelet counts but slightly lower nadirs were experienced with CNF therapy than with CAF. However, there were fewer dosage decreases with CNF. Significantly less nausea and vomiting were observed with the CNF regimen compared to CAF. Moreover, alopecia was reduced appreciably in patients who received CNF. The response rate to CNF for the first 38 eligible and evaluable patients was 42{\%}, and for 53 eligible and evaluable patients who received CAF the response rate was 45{\%}, a non-significant difference. Median response durations were similar also, 140 days for CNF and 168 days for the CAF regimen. Time to treatment failure was similar for both regimens. CNF is an effective regimen for patients with advanced breast cancer, with less toxicity than CAF.",
keywords = "Adriamycin, advanced breast cancer, combination chemotherapy, Novantrone",
author = "Bennett, {John M.} and Patrick Byrne and Ajit Desai and Charles White and Ronald DeConti and Charles Vogel and Edward Krementz and Franco Muggia and James Doroshow and David Plotkin and Harvey Golomb and Hyman Muss and Harvey Brodovsky and Richard Gams and Horgan, {Lee Roy} and Shelley Bryant and Arnold Weiss and Kenneth Cartwright and Gary Dukart",
year = "1985",
month = "6",
day = "1",
doi = "10.1007/BF00174167",
language = "English",
volume = "3",
pages = "179--185",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

AU - Bennett, John M.

AU - Byrne, Patrick

AU - Desai, Ajit

AU - White, Charles

AU - DeConti, Ronald

AU - Vogel, Charles

AU - Krementz, Edward

AU - Muggia, Franco

AU - Doroshow, James

AU - Plotkin, David

AU - Golomb, Harvey

AU - Muss, Hyman

AU - Brodovsky, Harvey

AU - Gams, Richard

AU - Horgan, Lee Roy

AU - Bryant, Shelley

AU - Weiss, Arnold

AU - Cartwright, Kenneth

AU - Dukart, Gary

PY - 1985/6/1

Y1 - 1985/6/1

N2 - As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were postmenopausal and 44% of CNF patients and 57% of CAF patients were estrogen receptor (ER) negative. Slightly over 30% of all patients had received hormonal therapy or chemotherapy in an adjuvant setting. Hematologic toxicity was similar in regard to platelet counts but slightly lower nadirs were experienced with CNF therapy than with CAF. However, there were fewer dosage decreases with CNF. Significantly less nausea and vomiting were observed with the CNF regimen compared to CAF. Moreover, alopecia was reduced appreciably in patients who received CNF. The response rate to CNF for the first 38 eligible and evaluable patients was 42%, and for 53 eligible and evaluable patients who received CAF the response rate was 45%, a non-significant difference. Median response durations were similar also, 140 days for CNF and 168 days for the CAF regimen. Time to treatment failure was similar for both regimens. CNF is an effective regimen for patients with advanced breast cancer, with less toxicity than CAF.

AB - As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were postmenopausal and 44% of CNF patients and 57% of CAF patients were estrogen receptor (ER) negative. Slightly over 30% of all patients had received hormonal therapy or chemotherapy in an adjuvant setting. Hematologic toxicity was similar in regard to platelet counts but slightly lower nadirs were experienced with CNF therapy than with CAF. However, there were fewer dosage decreases with CNF. Significantly less nausea and vomiting were observed with the CNF regimen compared to CAF. Moreover, alopecia was reduced appreciably in patients who received CNF. The response rate to CNF for the first 38 eligible and evaluable patients was 42%, and for 53 eligible and evaluable patients who received CAF the response rate was 45%, a non-significant difference. Median response durations were similar also, 140 days for CNF and 168 days for the CAF regimen. Time to treatment failure was similar for both regimens. CNF is an effective regimen for patients with advanced breast cancer, with less toxicity than CAF.

KW - Adriamycin

KW - advanced breast cancer

KW - combination chemotherapy

KW - Novantrone

UR - http://www.scopus.com/inward/record.url?scp=0021876918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021876918&partnerID=8YFLogxK

U2 - 10.1007/BF00174167

DO - 10.1007/BF00174167

M3 - Article

C2 - 3894279

AN - SCOPUS:0021876918

VL - 3

SP - 179

EP - 185

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -